Skip to main content

Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Abstract Aim: 

There is currently no well-accepted therapy for central nervous system Langerhans cell histiocytosis (CNS-LCH), a neuroinflammatory disease clinically characterized by often progressive, neurological symptoms including ataxia, dysarthria, dysphagia, hypertonicity, intellectual impairment and behavioural abnormalities. We applied immunomodulative/anti-inflammatory treatment on a patient with progressive CNS-LCH disease. Method: 

Intravenous immunoglobulin (IVIG) was administered monthly for 15 years to a patient with severe, image-verified neurodegenerative CNS-LCH. Results: 

During the IVIG treatment, the neurological deterioration initially appeared to be haltered, but over time there was still some deterioration. Conclusions: 

IVIG may be beneficial in partly haltering CNS-LCH neurodegeneration, but further studies are needed.

Keywords: Central nervous system; Intravenous immunoglobulin; Langerhans cell histiocytosis; Therapy

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1651-2227.2010.02125.x

Publication date: July 1, 2011

bpl/apa/2011/00000100/00000007/art00013
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more